Showing results (121-130 of 466) with videos related to
Sort By:
Pageof 47
Journal of Immunology (Baltimore, Md. : 1950)|August 1, 1989
Selective abrogation of alloreactivity via priming in the presence of aphidicolin, a specific inhibitor of DNA polymeraseS Morecki, S Slavin, S A Ben-SassonScandinavian Journal of Immunology|August 1, 1995
Induction of tolerance to experimental anti-phospholipid syndrome (APS) by syngeneic bone marrow cell transplantationM Blank, Y Tomer, S Slavin, et al.Transplant International : Official Journal of the European Society for Organ Transplantation|June 1, 1991
Treatment of pure red-cell aplasia following major ABO-mismatched T-cell-depleted bone marrow transplantation. Two case reports with successful response to plasmapheresisR Or, E Naparstek, N Mani, et al.Leukemia Research|January 1, 1996
The novel immunomodulator, Linomide, stimulates interleukin-2-induced human natural killer (NK) cell and PHA-stimulated T cell proliferation from normal donorsR Condiotti, S Slavin, V Barak, et al.Cancer Research|September 10, 1998
Allogeneic cell therapy for a murine mammary carcinomaS Morecki, E Yacovlev, A Diab, et al.Bone Marrow Transplantation|April 1, 1987
Purging breast cancer cells in preparation for autologous bone marrow transplantationS Morecki, F Pavlotzky, S Margel, et al.Transplant Immunology|June 29, 2005
Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseasesI B Resnick, M Y Shapira, S SlavinBone Marrow Transplantation|February 18, 1998
A fludarabine-based protocol for bone marrow transplantation in Fanconi's anemiaJ Kapelushnik, R Or, S Slavin, et al.Medical Oncology (Northwood, London, England)|September 1, 1995
Role of interleukin-2 in human hematological malignanciesA Toren, A Ackerstein, S Slavin, et al.Journal of Hematotherapy|January 1, 1994
Treatment of chronic myelogenous leukemia with recombinant human interleukin-2 and interferon-alpha 2aA Nagler, A Ackerstein, V Barak, et al.Pageof 47